Invitae (Invitae) Common Stock : $0.0 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Invitae Common Stock?

Invitae's quarterly common stock increased from Mar. 2023 ($0.0 Mil) to Jun. 2023 ($0.0 Mil) and increased from Jun. 2023 ($0.0 Mil) to Sep. 2023 ($0.0 Mil).

Invitae's annual common stock increased from Dec. 2020 ($0.0 Mil) to Dec. 2021 ($0.0 Mil) and increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil).

Invitae Common Stock Historical Data

The historical data trend for Invitae's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Common Stock Chart

Invitae Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

0.01

0.02

0.03

Invitae Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Common Stock	Get a 7-Day Free Trial															0.02	0.03	0.03	0.03	0.03

Invitae Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Invitae (Invitae) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

NVTA:Mexico IV8:Germany

Address

1400 16th Street, San Francisco, CA, USA, 94103

Website

https://www.invitae.com

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Executives

Ana J. Schrank	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley	officer: Chief Commercial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey	officer: See Remarks	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons	officer: See remarks	2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum	officer: Chief Medical Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida	officer: General Counsel	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight	officer: Chief Operating Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne	director	1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George	director, officer: CEO	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer	officer: Chief Financial Officer	1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland	officer: Chief Commercial Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse	director	3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers	director, other: President, Oncology	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301